アブストラクト
| Title | [集中治療室での薬の使い方] 抗菌薬 |
|---|---|
| Subtitle | 特集 エキスパートが直伝! 敗血症の薬学的管理 最新版 |
| Authors | 安藤里英, 岡田直人, 座間味義人, 石澤啓介 |
| Authors (kana) | |
| Organization | 徳島大学病院薬剤部 |
| Journal | 月刊薬事 |
| Volume | 63 |
| Number | 9 |
| Page | 1746-1751 |
| Year/Month | 2021 / 7 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points] ●敗血症における初期治療では, 感染臓器や患者背景などから起因菌を想定し, それらを過不足なくカバーする抗菌薬を選択する. ●特に初期治療では耐性菌リスクを適切に評価し, それに応じて広域抗菌薬を使い分ける. ●「日本版敗血症診療ガイドライン2020」では, 感染臓器ごとに頻度の多い起因菌と初期治療に使用する抗菌薬についてまとめている. ●敗血症時は腎機能が短時間で劇的に変化するため, 血清クレアチニン値だけでなく, その推移や尿量などを含め総合的に評価する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Khawcharoenporn T, et al : Active monotherapy and combi-nation therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents, 52 : 828-834, 2018
- 2) Gallagher JC, et al : Ceftolozane-tazobactam for the treat-ment of multidrug-resistant Pseudomonas aeruginosa in-fections: A multicenter study. Open Forum Infect Dis, 5 : ofy280, 2018
- 3) Haidar G, et al : Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: Clinical effectiveness and evolution of resistance. Clin Infect Dis, 65 : 110-120, 2017
- 4) McKinnell JA, et al : A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol, 34 : 1077-1086, 2013
- 5) Harris PNA, et al : Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA, 320 : 984-994, 2018
残りの8件を表示する
- 6) Seo YB, et al : Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis, 17 : 404, 2017
- 7) Doi A, et al : The efficacy of cefmetazole against pyelo-nephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis, 17 : e159-e163, 2013
- 8) Popejoy MW, et al : Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneu-moniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother, 72 : 268-272, 2017
- 9) Abe T, et al : Variations in infection sites and mortality rates among patients in intensive care units with severe sepsis and septic shock in Japan. J Intensive Care, 7 : 28, 2019
- 10) Ogura H, et al : Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study. J Infect Chemother, 20 : 157-162, 2014
- 11) Sime FB, et al : Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol, 24 : 1-6, 2015
- 12) Rybak MJ, et al : Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm, 77 : 835-864, 2020
- 13) 堀 誠治 : 抗菌薬の副作用とその発現機序 ; 濃度依存的な副作用を中心に. 日本化学療法学会雑誌, 52 : 293-303, 2004
